93%mRNA,6.9%JJ

For the post-vaccination analysis, we studied 284,592 patients (age 

52 ± 20 years; 57% female; 63% White, 10% Asian, 8.9% African Ameri-

can and 12% Hispanic ethnicity). The types of vaccinations received 

included: 62% Pfizer-BioNTech (BNT162b2); 31% Moderna (mRNA-1273); 

6.9% Johnson & Johnson/Janssen (Ad26.COV2.S); and <0.1% other vac-

cines, including AstraZeneca (ChAdOx1-S), Novavax (NVX-CoV2373) 

and Sinovac (CoronaVac).